Your browser doesn't support javascript.
loading
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
Wehler, Elizabeth; Boytsov, Natalie; Nicolay, Claudia; Herrera-Restrepo, Oscar; Kowal, Stacey.
Afiliação
  • Wehler E; IQVIA, 1 IMS Drive, Plymouth Meeting, PA, 19462, USA. beth.wehler@iqvia.com.
  • Boytsov N; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
  • Nicolay C; Lilly Deutschland GmbH, Bad Homburg, Germany.
  • Herrera-Restrepo O; IQVIA, 3110 Fairview Park Drive, Falls Church, VA, 22042, USA.
  • Kowal S; IQVIA, 3110 Fairview Park Drive, Falls Church, VA, 22042, USA.
Pharmacoeconomics ; 38(1): 123, 2020 Jan.
Article em En | MEDLINE | ID: mdl-31712980
ABSTRACT
Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2020 Tipo de documento: Article